Trial Profile
A phase II study of bevacizumab in patients with nonresectable cancer of the adrenal cortex
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Adrenal cancer
- Focus Therapeutic Use
- 11 Jul 2007 New trial record.